Rapid Dose Therapeutics Corp. (CSE:DOSE)
BURLINGTON, ONTARIO, CANADA, September 29, 2020 /EINPresswire.com/ — RAPID DOSE THERAPEUTICS AMENDS AGREEMENT WITH APHRIA TO PRODUCE IN BURLINGTON, ONTARIO FACILITY
BURLINGTON, Ontario – September 28, 2020 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”)
(CSE: DOSE), a Canadian life sciences company focused on innovative drug and active ingredient
delivery solutions, is pleased to announce it has amended the agreement with Aphria Inc. (TSE:APHA, Nasdaq:APHA) signed Nov 1, 2018. The amended agreement enables RDT to produce the QuickStrips at its licensed Burlington facility for Aphria.
As part of the amendment, Aphria relinquishes its global exclusive preferred vendor status enabling RDT to enter new markets with other licensed producers. Mark Upsdell, RDT CEO, adds “This change is consistent with the way we prefer to access developing markets. Non-exclusivity enables RDT to reach more Canadian medical and recreational users than available through a single customer strategy and opens up global opportunities. We also look forward to establishing agreements in emerging markets to provide the innovative QuickStrip.”
Jason Lewis, RDT SVP Business Development said “This is an exciting step forward providing us the capability of producing QuickStrips for Canadian licensed producers seeking product delivery diversification. Adults who use medical and recreational cannabis will benefit from our proprietary delivery technology that offers a Quick, Convenient, Precise, and Discreet™ way to consume CBD and THC.”
Upsdell adds, “RDT and Aphria have had a long term relationship that is continuing to evolve as business plans, processes and markets change in Canada and internationally. Moving Aphria strip production into RDT’s own facility enables RDT to focus on its core competencies.
With regards to the CTO, the Company is working diligently with its auditors on the completion of its Annual Filings. In addition to its annual filings, the company is also working towards the completion and filings of its MDNA and first quarter filings.
About Rapid Dose Therapeutics.
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian Life Sciences company providing innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry — including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT also provides a turn-key Managed Strip Service Program enabling RDT’s QuickStrip™ proprietary cannabis delivery technology to be licensed to select operators in identified markets. RDT’s service-based annuity contracts drive recurring revenue and facilitate rapid expansion into emerging markets across multiple consumer segments. RDT is committed to continually create innovative solutions for humans, animals and plants.
For more information, visit: www.rapiddose.ca
For inquiries please contact:
Ofc (416) 477-1052
Managing Director Capital Markets
Ofc (416) 365-8012
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws.
Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues and the dismissal of the CTT lawsuit, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
MARK A UPSDELL
Rapid Dose Therapeutics Corp.
email us here
Source: EIN Presswire